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Abstract 
Background: Hypoglycemia is a critical and limiting factor of a good metabolic control and can adversely affect the 
quality of life of diabetic patients. The aim of the study was to evaluate the health-related quality of life and calculate 
utilities values associated with hypoglycemia in patients with type 1 diabetes mellitus (T1DM).
Methods: A multicenter, cross-sectional and observational study with T1DM patients from reference centers of the 
Brazilian public health system was conducted in three cities. Demographic and clinical data were collected, besides 
details on the frequency and severity of hypoglycemia. Health-related quality of life was assessed using EQ-5D instru-
ment and utility values generated.
Results: 221 patients (107 women, 114 men), aged 29.8 ± 11.6 and disease duration of 14.2 ± 9.1 years were 
included. Most patients (n = 214, 96.8%) reported at least one symptomatic hypoglycemia in the last three months, 
68% (n = 150) reported nocturnal episodes and 34.8% (n = 77) reported severe episodes. High frequency (daily or 
weekly) was observed in 38.6 and 26% of those reporting nocturnal or severe hypoglycemia, respectively. The median 
visual analog scale was 70 [60–85] for all patients, with differences between those with and without severe hypogly-
cemia (70 [60–80] vs 80 [61–90]; p = 0.006) and those with high and low frequency (62.5 [50–72.25] vs 70 [60–80]; 
p = 0.007). The median utility values was 0.801 [0.756–1.000] for all patients, with difference between those with high 
and low frequency of severe episodes (0.737 [0.628–1.000] vs 0.801 [0.756–1.000]; p = 0.02).
Conclusions: This study shows the high frequency of hypoglycemia in a sample of T1DM patients treated in three 
reference centers of the Brazilian public health system and the impact of severe episodes on health-related quality of 
life. Utility values were generated and can be used in economic analysis for treatments that could decrease hypogly-
cemia and consequently improve quality of life.
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Background
Hypoglycemia is a common event in the lives of patients 
with type 1 diabetes mellitus (T1DM) and carries high 
morbidity. The goal of diabetes treatment is to achieve 
euglycemia without episodes of hypoglycemia, but the 
frequent occurrence of hypoglycemia is a critical and 
limiting factor of a good metabolic control in the short 
and long-term [1]. The episodes may be asymptomatic 
and go undetected, quickly leading to alterations of 
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uncomfortable and disturbing symptoms associated with 
decreased quality of life. Often patients with diabetes fear 
more the severe hypoglycemic episodes than the chronic 
complications of the disease [2]. Hypoglycemia can have 
several effects on the health-related quality of life, like 
the acute unpleasant symptoms of the episode itself, fear 
of risk situations and future episodes, anxiety and reluc-
tance to implement intensive insulin regimen to better 
metabolic control [3].
The quality of life and utilities are different con-
cepts, however, are related to each other. The concept 
of utility originates in economic theory that deals with 
decision making and seeks to develop a model to repre-
sent how individuals make decisions when faced with 
uncertain conditions of health, based on their individ-
ual preferences [4]. Utility values are obtained request-
ing individuals to make judgments about their health 
status, changes in health status or outcomes, and aim 
to summarize a variety of aspects and concepts related 
to health and quality of life in a unique measure [5].
From utility data, it is possible to calculate quality-
adjusted life years (QALY), which is a very appropriate 
measure for clinical effectiveness in economic analyzes 
(cost-utility studies) in certain contexts and diseases, 
such as diabetes. There are several methodological 
approaches to estimate utilities, for example, by validated 
questionnaires (EQ-5D, SF-6D and HUI3) or discrete 
choice experiments. In the present study, we opted for 
using EuroQol (EQ-5D) [6] that is a generic and multidi-
mensional tool that has already been successfully applied 
in many studies and in several countries, including Brazil 
[7]. These results can be used for economic evaluations 
of interventions (prevention, management or treatment) 
that can affect the quality of life of patients with diabetes.
The aim of the study was to evaluate the health-related 
quality of life and calculate utilities values associated with 
hypoglycemia in patients with type 1 diabetes mellitus 
treated in reference centers of the Brazilian Public Health 
System.
Methods
A multicenter, cross-sectional and observational study 
that collected data from patients with T1DM on health-
related quality of life and hypoglycemia.
The study aimed to recruit 300 patients with T1DM in 
three public reference centers: Instituto da Criança com 
Diabetes-ICDRS, Porto Alegre; Instituto de Endocrino-
logia e Diabetes Luiz Capriglione-IEDE, Rio de Janeiro e 
Centro Integrado de Diabetes e Hipertensão-CIDH, For-
taleza. Included patients had clinical and laboratory diag-
nosis of T1DM and more than 18 years. Individuals with 
any physical or mental conditions that limit the under-
standing and answering of the questions were excluded.
They were recruited consecutively according to the 
eligibility criteria and attendance to their medical con-
sultations. Patients answered a structured questionnaire 
administered by a trained interviewer. The questionnaire 
included demographic data, information of the disease 
and its treatment, presence of associated medical condi-
tions, information on intensity and frequency of hypogly-
cemia and health-related quality of life (EQ-5D and visual 
analogue scale-VAS).
All subjects were invited to participate and signed a 
term of consent. The study protocol was submitted to 
the Research Ethics Committee of each of the executing 
centers.
Hypoglycemia
Hypoglycemic events were classified as:
1. Symptomatic hypoglycemia: an event during which 
typical symptoms of hypoglycemia accompanied or 
not by a measurement of glucose concentration in 
plasma ≤70 mg/dl.
2. Severe hypoglycemia: an event that requires assis-
tance from another person to actively adminis-
ter carbohydrate, glucagon, or other resuscitative 
actions.
3. Nocturnal hypoglycemia: a symptomatic event (doc-
umented or not), severe or not, which occurred after 
10 p.m. until dawn.
The frequency of hypoglycemic events was defined as 
daily, weekly, monthly or at least one episode in the last 
3 months. High frequency was considered those individ-
uals with daily or weekly episodes, and low frequency for 
the others.
Health‑related quality of life and utility values
The EQ-5D is a generic instrument that assesses the qual-
ity of life through 5 domains: mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression. For 
each item, there is gradation 1, 2 and 3 (no problem, 
some problems and extreme problems), respectively). 
Combining the results of these five scores produces 243 
different health states.
The utility values vary, usually from 0 (equivalent to 
death) to 1 (equivalent to perfect health), while negative 
values (worse than death) can be obtained. The different 
possible health states are judged from this score from 0 to 
1, that is from a conceptual point of view, are valued by 
reference to death states and perfect health.
For each health state generated by EQ-5D, a value of 
utility was assigned according to the valuation parame-
ters of health status obtained from the Brazilian valida-
tion study [7].
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Statistical analysis
The descriptive analysis of the results is presented in 
terms of mean or median and standard deviation or vari-
ance. We used the Mann–Whitney test for comparisons 
on VAS and utility values. The Kruskal–Wallis test was 
used to compare categorical variables.
Results
We included 221 patients, 107 women and 114 men, 
mean age 29.8 ± 11.6 years, BMI 23.7 ± 4 kg/m2 and dis-
ease duration of 14.2 ± 9.1 years.
All patients were using rapid and basal insulins. 
The basal insulin mean dose was 39.5  ±  15.2 and 
17.8 ± 10.4 U/day for rapid insulin. Most of the popula-
tion (74.8%) used NPH insulin as basal insulin, with 55 
patients (25.5%) in use of long-action analogs (47 patients 
with insulin Glargine and 8 with Detemir). The rapid-
acting analogs were used by 63.4% of the population 
(18 Aspart, 119 Lispro and 2 Glulisine ), the others used 
regular insulin (Table  1). There were two patients with 
incomplete data on treatment.
Most patients (n = 179, 80.9%) reported that they fol-
lowed the treatment recommendations partially, 21 
patients (9.5%) followed all the treatment recommen-
dations, while 17 patients did not follow any guidance 
(7.69%). Carbohydrate counting was performed by 83 
patients (37.8%).
Regarding chronic complications of diabetes and 
associated medical conditions, 19.4% reported having 
nephropathy, 21.7% retinopathy, 21.8% neuropathy, 13.6% 
were hypertensive, 0.9% reported coronary heart disease 
and 1.8% reported a previous episode of stroke.
The frequency and severity of hypoglycemia episodes 
are displayed in Table 2.
The median value of the visual analogue scale (VAS) 
was 70 [60–85] and the median utility value was 0.801 
[0.756–1.000]. Tables  3 and 4 show the VSA and util-
ity values according to the categories and frequency 
of hypoglycemia. Figures  1 and 2 demonstrate the 
utility and VAS according to the frequency of severe 
hypoglycemia.
Discussion
The present study aimed to collect data from a group 
of patients with T1DM treated in the Brazilian Pub-
lic Health System (SUS) for generating information on 
health-related quality of life and utility values associ-
ated to hypoglycemia. The study population was derived 
from reference centers for the treatment of T1DM in 
the South, Southeast and Northeast regions of Brazil. 
The treatment with basal-bolus regimen was done by all 
patients, with 25.5% using slow-acting insulin analogs 
and 63.4% using rapid-acting analogs. Approximately 
20% already had chronic complications of diabetes and 
only 9.5% followed all the treatment recommendations 
correctly.
As expected, most of the population reported epi-
sodes of hypoglycemia in the last 3  months, with 68 
and 34% reporting nocturnal and severe hypoglycemia, 
respectively. Of the patients who had severe hypoglyce-
mia, requiring third-party help for their recovery, 26% 
reported high frequency of episodes.
We observed the perception of diabetic patients in 
relation to their health by Visual Analogue Scale assess-
ment. The result was slightly lower than that found in the 
Brazilian multicenter study of 3.005 T1DM patients (70 
vs 72.5) [8] and much lower than the national average 
obtained in the sample of 9.148 healthy subjects of simi-
lar age (70 vs 82.1) [7]. The comparison of VAS and utility 
values between groups with and without hypoglycemia 
did not showed significant difference, but the patients 
with severe hypoglycemia and those with high frequency 
of episodes (daily or weekly) had lower values than 
patients who did not report these episodes. These results 
are consistent with previous studies that have shown that 
hypoglycemia negatively influences quality of life in type 
2 [9, 10] and type 1 diabetic patients [11].
The evaluation of health-related quality of life has been 
increasingly recognized as an important area of scien-
tific knowledge, as it takes into account various aspects 
of the patient’s life, physical and mental well-being, and 
Table 1 Treatment according to insulin types
Basal insulins Rapid insulins
N = 219 N = 219
NPH 164 (74.48%) Regular 80 (36.5%)
Glargine 47 (21.8%) Aspart 18 (8.2%)
Detemir 8 (3.7%) Lispro 119 (54.3%)
Glulisina 2 (0.9%)
Table 2 Frequency and severity of hypoglycemia episodes
a Any symptomatic hypoglycemia excluding nocturnal or severe episode
Frequency (%) Hypoglycemiaa Nocturnal Severe
N = 214 (96.8%) N = 150 
(68.1%)
N = 77 (34.8%)
Daily 27 (12.6%) 5 (3.3%) 2 (2.6%)
Weekly 104 (48.6%) 53 (35.3%) 18 (23.4%)
Monthly 67 (31.3%) 56 (37.3%) 19 (24.7%)
Once (last 
3 months)
16 (7.5%) 36 (24%) 38 (49.3%)
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Table 3 Visual analogue scale and utility values according to the categories of hypoglycemia
Categories Visual analogue scale Utility
Q1 Median Q3 p value Q1 Median Q3 p value
Hypoglycemia
 No 50 70 85 0.787 0.801 1.000
 Yes 60 70 85 0.39 0.756 0.801 1.000 0.76
Nocturnal hypoglycemia
 No 60 75 85 0.787 0.801 1.000
 Yes 60 70 85 0.27 0.756 0.801 1.000 0.9
Severe hypoglycemia
 No 61 80 90 0.787 0.801 1.000
 Yes 60 70 80 0.006 0.737 0.801 1.000 0.14
Table 4 Visual analogue scale and utility values according to the frequency of nocturnal and severe hypoglycemia
§ Between low and high frequency of hypoglycemia
a Low frequency: one monthly episode or one in the last 3 months
b High frequency: daily or weekly episodes
Categories Visual analogue scale Utility
Q1 Median Q3 p value Q1 Median Q3 p value
Nocturnal hypoglycemia
 Absent 60 75 85 0.756 0.801 1.000
 Lowa 60 70 85 0.787 0.801 1.000
 Highb 60 70 81.25 0.40§ 0.737 0.801 1.000 0.74§
Severe hypoglycemia
 Absent 61 80 90 0.787 0.801 1.000
 Lowa 60 70 80 0.756 0.801 1.000
 Highb 50 62.5 72.25 0.007§ 0.728 0.737 1.000 0.02§
Fig. 1 Utility values in patients with severe hypoglycemia (frequent  
or rare) Fig. 2 Visual analogue scale in patients with severe hypoglycemia 
(frequent or rare)
Page 5 of 5Bahia et al. Diabetol Metab Syndr  (2017) 9:9 
satisfaction with treatments. Several assessment tools 
have been proposed to evaluate specifically the diabetic 
population, but many of them have not yet been vali-
dated in Brazil [12]. A limitation of this study was the 
use of a generic instrument for quality of life assessment, 
that although often used and previously validated in Bra-
zil, which allows comparison with other populations, is 
not specific to diabetes and therefore has limitations in 
reaching some aspects of T1DM patients’ lives.
There are now a substantial number of studies report-
ing utility scores for people with diabetes and for com-
mon complications associated with the disease [13]. 
Health technology assessment agencies around the world 
have consistently adopted the inclusion of utilities (or 
disutilities) associated with health interventions in eco-
nomic analysis of new technologies. The premise is that 
possible effects of treatments can add utility decrements 
or increments and, therefore, should be considered as a 
parameter for evaluation beyond the efficacy.
Based on the data from the National Euroqol validation 
study [7], it was possible to obtain, for the first time util-
ity values specifically for the Brazilian population with 
T1DM and related to hypoglycemia. Although the val-
ues were not different between diabetic patients with and 
without hypoglycemia, possibly by the small sample size, 
it was observed that patients who had a high frequency 
of severe hypoglycemias reported a worse perception of 
their health status. It must be taken into consideration 
in treatment decisions by prescribers and health pol-
icy makers, especially when thinking of populations of 
children.
Conclusion
This study shows the high frequency of hypoglycemia 
in a sample of T1DM patients treated in three refer-
ence centers of the Brazilian public health system and 
the impact of severe episodes on health-related qual-
ity of life. Utility values were generated and can be 
used in economic analysis for treatments that could 
decrease hypoglycemia and consequently improve 
quality of life.
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